Ricci Gabriele 4

What Happened
Gabriele Ricci, Chief Data & Technology Officer at Takeda Pharmaceutical Co. (TAK), was granted 37,616 restricted stock units (RSUs) on July 1, 2026. The grant is reported at $0.00 per unit (no cash paid at grant) and a reported total value of $0 on the Form 4 because RSUs are a contingent equity award rather than an open-market purchase.

Key Details

• Transaction date: July 1, 2026. Form 4 filed July 6, 2026 (5 days after the transaction). This appears later than the typical two-business-day Form 4 reporting window.
• Transaction type/code: A — Award/Grant of RSUs.
• Amount: 37,616 RSUs; reported price $0.00; reported transaction value $0.
• Shares/ownership after transaction: Not disclosed in this filing.
• Footnote (F1): Each RSU represents a contingent right to receive one American Depositary Share (ADS). RSUs vest in three equal annual installments beginning July 1, 2027.
• Tax withholding / other codes: None reported on the Form 4.

Context
RSU grants are a common form of executive compensation and vest over time; they are not an immediate purchase or sale and do not necessarily indicate near-term buying or selling intent. Because vesting is staggered (three equal annual installments starting 7/1/2027), the economic benefit to the insider is realized later as units convert to ADSs upon vesting.